Invert Bioprocess Secures $20.1M Seed Funding to Revolutionize Bioprocess Data Transparency

Invert Bioprocess is proud to announce that it has successfully raised $20,100,000 in its latest funding round—a transformative milestone for a company at the forefront of revolutionizing bioprocessing software. Specializing in comprehensive solutions for biopharma, synthetic biology, and CDMOs, Invert’s cutting-edge technology provides full transparency into every facet of bioprocess data, spanning from the laboratory bench to full-scale production. This infusion of capital will accelerate the company’s mission to streamline data management processes across the bioprocessing spectrum by eliminating cumbersome manual data entry, enhancing traceability from upstream operations to final formulations, and empowering teams with actionable insights. The new funds will be strategically invested in scaling their software platform, driving technology innovation, and expanding market reach—all while strengthening the company’s research and development capabilities to stay ahead in an increasingly competitive industry. With this investment, Invert is set to deliver even greater value to its customers by enabling real-time collaboration amongst interdisciplinary teams and global partners, ensuring that every stakeholder has access to the most accurate, up-to-date process data. As the bioprocessing landscape continues to evolve, Invert’s commitment to transforming complex data into clear, actionable intelligence stands to redefine operational efficiency and decision-making throughout the industry. This announcement not only marks a significant financial vote of confidence in Invert’s vision and capabilities but also reinforces the company’s role as a trusted partner dedicated to driving innovation and excellence in bioprocessing worldwide.